Shots:
- CSL has reported topline P-IIIb results evaluating Andembry (garadacimab-gxii) in children aged 2 to 11yrs. with hereditary angioedema (HAE)
- Pts aged 6–11 years received 100mg (QM, n=16), while those aged 2–5yrs. received 100mg (Q2M, n=6). Andembry showed a favorable safety profile & treatment response, with most pts remaining attack-free over 12mos.
- Full results will be presented at a scientific congress & published in a journal, with CSL planning to submit regulatory filings in H1 of its fiscal year to expand Andembry indication in this population
Ref: PRnewswire | Image: CSL | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
